Somewhat Positive Media Coverage Somewhat Unlikely to Impact Pain Therapeutics (NASDAQ:PTIE) Stock Price

Press coverage about Pain Therapeutics (NASDAQ:PTIE) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pain Therapeutics earned a news impact score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.8176948086765 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

PTIE stock opened at $7.38 on Friday. Pain Therapeutics has a 1 year low of $3.10 and a 1 year high of $12.80. The stock has a market capitalization of $49.44, a PE ratio of -4.05 and a beta of 2.58.

Pain Therapeutics (NASDAQ:PTIE) last posted its earnings results on Monday, February 5th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter. analysts expect that Pain Therapeutics will post -1.65 EPS for the current year.

Several analysts have recently issued reports on PTIE shares. Zacks Investment Research lowered Pain Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 27th. ValuEngine lowered Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Pain Therapeutics (NASDAQ:PTIE) Stock Price” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at

Pain Therapeutics Company Profile

Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.

Insider Buying and Selling by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply